60 Degrees Pharmaceuticals (SXTPW) Stock Price, News & Analysis

Company Overview

60 Degrees Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing treatments for infectious diseases, particularly malaria and other diseases that are under-served by existing therapies. Founded in 2010, the company is based in Washington, D.C.

Its marketed product, ARAKODA (tafenoquine), is approved by the U.S. Food and Drug Administration to prevent malaria in adults. The company also conducts research into potential uses of tafenoquine for other infectious diseases, including babesiosis.

60 Degrees Pharmaceuticals’ commercial activities include making ARAKODA available in the United States, while its research programs aim to expand treatment options for patients affected by infectious diseases.

Key Stats

• Today's Range: $0.02 to $0.03
• 50-Day Range: $0.02 to $0.04
• 52-Week Range: $0.02 to $0.15
• Volume: 24,095 shs
• Average Volume: 9,166 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:SXTPW
• CIK: 1946563
• Web: 60degreespharma.com
• Phone: 202-327-5422
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $1.11 million
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A